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Abstract 
Immunoassay procedures have a wide application in clinical medicine and as such are used 
throughout clinical biochemistry laboratories both for urgent and routine testing. Clinicians and 
laboratory personnel are often presented with immunoassay results which are inconsistent with 
clinical findings. Without a high index of suspicion interferences will often not be suspected. 
Artifactual results can be due to a range of interferences in immunoassays which can include cross 
reacting substances, heterophile antibodies, autoantibodies and the high dose hook effect. Further, 
pre-analytical aspects and certain disease states can influence the potential for interference in 
immunoassays. Practical solutions for investigation of artifactual results in the setting of the routine 
clinical laboratory are provided. 
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 The investigation of interferences in immunoassay  
Introduction 
Most clinicians accept laboratory results at face value and do not query the validity of that result. For 
this reason the laboratory has a particular responsibility to ensure the validity of the results they 
release. 
Immunoassay is an important part of the diagnostic pathology laboratory, and because of the 
relatively low concentrations of analyte being measured and because of the complexities of the 
antigen-antibody interaction, this technique is relatively susceptible to interferences. 
In some areas, possible interferences may be highly problematic and highly visible. A good example 
is with the use of troponin in assessing the person with possible acute coronary syndrome. The 
presence of troponin is a core part of the diagnosis of myocardial infarction and results are 
frequently required urgently. We have had patients present with a relatively constant concentration 
of troponin regardless of whether they are experiencing chest pain, suggesting that the apparent 
troponin result is artifactual. With such patients it is of considerable importance to sort out what is 
happening – is an interferent present or is the troponin result real? 
However, with many assays there may never be reason to suspect the presence of an interferent as 
the results may be open to interpretations that can handle a variety of results. An example of this is 
serology looking at possible infections, where either a negative or a positive result can be 
rationalised on clinical grounds. 
The purpose of this review is not so much to identify the mechanisms of immunoassay interferences 
– there have been many excellent reviews published on this topic [1- 8] – but rather to discuss ways 
of becoming aware of possible interferences and how to investigate them. We have deliberately 
concentrated on relatively simple procedures that will be available in non-specialist laboratories. 
 
The nature of interferences  
An interference is defined as the effect of a substance present in the sample that alters the correct 
value of the result [9]. There are many possible reasons for false results to be obtained during an 
immunoassay procedure and these are considered briefly below. 
Interferences in immunoassay fall in to 2 broad categories – analyte-independent and analyte-
dependent, as shown in Table 1. Analyte-independent problems are considered below in the section 
on the investigation of possible interferences. A summary of analyte-dependent interferences is 
presented below. 
 
Analyte-dependent interferences 
Cross-reacting substances 
One of the beauties of immunoassay is the unique specificity of the antibody for the analyte. One of 
the problems of immunoassay is that where structural differences are very small, e.g. cortisol and 
prednisolone, there may be substantial cross-reactivity. To demonstrate this point, in Table 2 we 
have assembled data on cross-reactivity for cortisol assays from different manufacturers in 2017. It 
is apparent that some important potential interferences such as prednisolone are detected to a very 
variable extent between different assays and further that assays from the same manufacturer may 
show marked changes in cross-reactivity over time. For example the Roche cortisol assay had 171% 
cross-reactivity with prednisolone in 2014 but an assay with new antibodies in 2017 had only 8% 
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cross-reactivity. While Roche did not comment on cross-reactivity of 5D-tetrahydrocortisol in 2017, 
in 2014 they acknowledged that it had a very high cross-reactivity in cortisol assays (165%). While 
5D-tetrahydrocortisol is predominantly a urinary metabolite (as a glucuronide), in persons with renal 
failure it might be anticipated to be in relatively high concentrations in plasma and discordant results 
have been observed in cortisol assays in patients with renal failure [10, 11]. Manufacturers are 
constantly changing their assays and it is essential to be aware of these potential interferences. 
Another example of significant cross-reactivity is with the immunosuppressant compound 
cyclosporine A. This compound is metabolised to a large number of metabolites with varying 
biological activity and varying cross-reactivity to the antibodies used in the assay, and for this reason 
some specialist centres use HPLC or LC-MS to assay the parent compound [12]. 
Heterophile antibodies 
Heterophile antibodies are naturally occurring, poly-specific, usually low affinity antibodies which 
after antigen exposure are replaced by high affinity antibodies [3]. Because of their relatively low 
affinity they usually interfere in assays to a lesser extent than human anti-animal antibodies (see 
below). Diagnostic companies now use a number of approaches to eliminate or minimise 
interference which include: addition of trace amounts of animal serum of the same animal species as 
used to raise the antibodies in the assay to assay reagents; addition of  non-specific animal 
immunoglobulin to reagents ; addition of heat-aggregated non-specific murine monoclonal antibody 
MAK33 to reagents; the use of F(ab’)2 fragments for the solid phase; and this is usually sufficient to 
block the interference by heterophile antibodies [7]. 
Human anti-animal antibodies (HAAA) 
In contrast to heterophile antibodies, HAAA are high affinity antibodies directed against specific 
animal immunoglobulins. Exposure to animals which are used for the preparation of the antibodies 
used in immunoassays is the trigger. Mice are of particular importance as murine antibodies are the 
most widely used in commercial immunoassay, and mice are ubiquitous in the environment. 
Figure 1 shows a potential mechanism of interference by antibodies in the typical 2-site assays used 
for protein analysis in the immunoassay laboratory.   
Autoantibodies 
Autoantibodies are endogenous antibodies directed against the body’s own components. Well 
known examples are macro-prolactin (macro-PRL) which is a complex of IgG and PRL [13], and anti-
thyroid peroxidise (anti-TPO) commonly found in autoimmune thyroiditis [14]. Autoantibodies have 
been described to many analytes including enzymes [15], TSH [16], thyroglobulin [17], insulin [18], 
thyroid hormones [19] and testosterone [20, 21], to name a few examples.  
Rheumatoid Factor (RF) is an autoantibody directed against the Fc portion of an individual’s IgG. It is 
common with up to 25% of older individuals having RF present in their blood [22]. RF has been 
identified as an interferent in several assays including cTnI [23] and thyroid hormones [24] 
Prolactin (PRL) exists primarily as a 23kD monomer, but may exist both as dimers and bound to an 
immunoglobulin, usually IgG. The immunoglobulin-bound form is known as macro-prolactin. Macro-
PRL is considered biologically inert, probably because its large molecular size prevents it from 
crossing capillary walls to exert its biological effects [25]. Thus macro-prolactinemia is effectively a 
benign condition. 
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However, all immunoassays for PRL recognize macro-PRL to some extent, and this can be 
problematic as women with benign macro-prolactinemia may be confused with women with true 
hyper-prolactinemia and be inappropriately treated. In some studies, macro-PRL may account for 
around 25% of cases of hyper-prolactinemia [13, 26]. Thus finding some way of identifying macro-
PRL from true hyper-prolactinemia was important. Lindstedt identified PEG precipitation as a 
possible means of rapidly and reliably separating monomeric- and macro-PRL in the diagnostic 
laboratory [27]. The use of PEG precipitation for identifying macro-PRL and other analytes is 
considered in the investigation of interferences below.  
IgG autoantibodies against cTnI have been known for many years. Interestingly one of the first 
reports was of a negative interference [28]. It appears that the autoantibodies are directed against 
cTnI but only when it is in the circulating cTnI-cTnC-cTnT (I-T-C) complex [29]. The prevalence of 
circulating antibodies to cTnI have been described as between 5% [30] and 12.5% [31]. This is much 
higher than seen in routine clinical practice and implies we are missing a substantial number of 
cases. The presence of cTnI appears to be associated with myocardial inflammation [32], so the 
presence of antibodies is a logical defence mechanism and perhaps explains why the prevalence of 
troponin auto-antibodies is so high. 
High dose hook effect 
The high dose hook effect can occur when an analyte being measured is present in very high 
concentrations. Whilst it can occur with 2-site immunometric assays, it is particularly a problem with 
nephelometric assays.  
In 2-site assays the excess antigen may prevent “sandwich” formation with capture and signal 
antibodies both being bound separately to the analyte, and signal antibody being washed away and 
a resultant apparent low concentration of analyte being recorded [2, 33]. 
Nephelometric assays rely on the formation of Heidelberger-Kendall complexes which are large and 
scatter light [34]. In the presence of antigen excess these large complexes do not form and the 
concentration of the analyte is under-estimated as shown in Figure 2.  
Any analyte which can be present in very high concentration, in particular tumour markers including 
prolactin and hCG may be prone to the high dose hook effect. 
 
Clues as to the presence of a possible interference 
There are 2 usual ways in which the possibility of an interferent may be suspected. 
1. Discordant results 
An example of a result that would raise suspicion of an interference would be if thyroid function 
tests were requested and the usual relationship of thyroid hormone (TT4 or fT4) and TSH was 
disturbed. Because of the sensitive negative feedback relationship between thyroid hormones 
and the secretion of pituitary TSH, these should exist in either high/low, euthyroid/euthyroid or 
low/high combinations. While for example a high/high relationship may indicate thyroid 
hormone resistance, an interference is far more likely by orders of magnitude. A low/low 
combination may reflect a sick euthyroid state but again an interference should be considered. 
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Some substances measured by immunoassay maintain a fairly constant concentration eg TSH. 
Others however, such as troponin are expected to show a distinct rise and fall. The presence of a 
constant moderately increased troponin does not fit an expected pattern and an interference 
may be suspected. Similarly, a failure of troponin to rise when an acute coronary syndrome is 
highly likely, may indicate a negative interference. 
TotalE-hCG is used to identify pregnancy and to identify malignancies in both females and 
males. The presence of detectable total E-hCG in a situation where pregnancy is unlikely needs 
to be viewed very cautiously as life-changing treatments may result. Any suggestion of 
discordance with the clinical setting should lead to a vigorous search for a possible interference. 
  
2. Clinical interaction 
If the laboratory is lucky, it will have good relations with clinical staff and they will be aware of 
the possibility of interferences as they view the results they receive. Communication between 
clinicians and the laboratory is a most important way of minimizing the release of bad results. 
  
 
The investigation of possible interferences  
A proposed sequence of investigations of possible interferences is shown in Table 3 and expanded 
below.  
1 High index of suspicion 
There have been a number of published studies looking objectively at the incidence of 
interferences in immunoassay, and these have shown that there is an underlying incidence 
of 3-4% of significant interferences [35, 36].    
The problem is largely managed by diagnostic companies by the addition of animal serum or 
immunoglobulins from the same animal species as the antibodies used in the assay [1]. 
However, these additions will not handle large amounts of heterophile antibody or HAAA. 
The prevalence of false results with these modified assays may still be as high as 0.53% [37]. 
While 2-site immunometric assays appear to be more prone to interferences than assays 
with other architecture, any form of immunoassay may be affected. Some areas of the 
clinical laboratory show much greater awareness of the problem of interferences. For 
example looking at PubMed in December 2016 for “immunoassay interferences”, of the 
most recent 200 articles only 6 related specifically to microbiology or serology with the 
majority relating to drugs and hormones. The implication is that in some areas of the lab 
many false results are being released because the index of suspicion is low.  
 
2 Exclude pre-analytical problems 
There are many potential pre-analytical causes of false results in immunoassay as shown in 
Table 1, and these should be methodically excluded. 
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While for some assays, only specific sample types are recommended – for example EDTA for 
ACTH estimation [38]– for most immunoassay analytes, a variety of matrices are acceptable. 
For convenience and to speed turn-around times, we often use Li-heparin samples on our 
main-frame analyzers. Heparin is a relatively poor anticoagulant and inadequate initial 
centrifugation, or extended time before sampling, can result in the formation of micro-clots 
which are notorious for generating spurious results in immunoassay. Re-centrifugation of 
samples may be necessary. 
 
Significant lipemia and hemolysis  may be problematic, particularly if nephelometric assays 
are used. We always check lipemic and haemolytic indices off our main frame analyzers to 
ensure this is not a problem as defined for each individual analyte. 
 
While it should not be a problem with modern instruments, the potential for carry-over 
should be considered [39]. Occasionally there will be extremely high concentrations of 
tumor markers or E-hCG and if there is inadequate washing of samples, the following sample 
may be contaminated and give an erroneously high result. 
 
Some analytes in blood will be highly protein-bound eg thyroxine and cortisol. Reliable 
measurement of total T4 or cortisol is dependent upon assay conditions ensuring total 
separation of the small hormone from its binding protein. 
 
Most immunoassays now use chemiluminescence as the signal in immunoassays utilising 
either acridinium esters or luminol derivatives and paramagnetic particles as a separation 
tool. Some use biotin-streptavidin as the separation tool [40] and ruthenium [41] for  an 
electrochemiluminescent signal. Antibodies to ruthenium have been reported [42] and also 
biotin [43]. Further, the therapeutic use of biotin [44] has  caused false results on 
immunoassay utilising biotin-streptavidin [45, 46]. 
 
Some disease states can cause artifactual changes in measured substances. For example 
during diabetic ketoacidosis, concentrations of free fatty acids rise in blood and these can 
cause displacement of thyroxine from its binding proteins with an artifactual increase in 
measured fT4. 
 
3 Repeat analysis on another instrument from a different manufacturer 
Most immunoassays nowadays use monoclonal antibodies (or affinity purified antibodies) 
directed against specific epitopes. Assays from different manufacturers are likely to be 
directed against different epitopes, potentially using antibodies originating from different 
animal species. If an assay for a particular analyte is run on a different instrument with a 
different assay design, significant discordance in results between the 2 assays may result and 
give the clue of an interference. 
   
A variant to this principle can be used with cardiac troponin assays. Whilst measuring quite 
different chemical entities, both cardiac troponin T (cTnT) and cardiac troponin I (cTnI) rise 
in similar fashion following acute myocardial infarction. Our routine assay is for cTnI and 
when we suspect an interference we run cTnT to see if the clinical profile is similar. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
8 
 
 
As discussed above under analyte-independent interferences, antibodies to ruthenium and 
therapeutic use of biotin may cause problems in assays which use these substances as part 
of their assay construction. In such a setting, repeating the assay on another instrument with 
different assay architecture is of great value. 
 
Occasionally use of monoclonal assays (or highly specific antibodies/assays) can be a 
problem. Monoclonal antibodies used for a particular assay are directed against a specific 
epitope, whilst polyclonal antibodies between them recognise many epitopes on that 
antigen. It is possible to have a benign mutation which does not affect biological function 
but which causes loss of one or more epitopes. If the monoclonal antibody used in a 
particular assay is directed against this missing epitope, a false low result will be obtained. 
Examples of these missing epitopes include LH [47] and PTH [48]. It is important where such 
an interference is suspected, to use a different assay with antibodies directed against a 
different epitope. Best of all is to use an assay with polyclonal antibodies but these are no 
longer widely available. 
 
4 Use of heterophile blocking tubes (HBTs) 
It is popularly assumed that use of heterophile blocking tubes will reliably identify the 
presence of an interfering substance. This is not necessarily so. There have been a number 
of studies reporting failure of HBTs to identify proven interferences [37, 49-52]. With one of 
the more commonly used HBTs from Scantibodies, it is acknowledged by the company that 
this HBT will not reliably work where the assay uses material derived from mice [53], and 
murine elements are very common in commercial immunoassays. When incubation with an 
HBT causes a significant change in result, it is likely that an interferent is present. However, 
lack of change is not evidence that there is no interference. 
 
5 Polyethylene glycol (PEG) precipitation  
The use of polyethylene glycol (PEG) for separating native prolactin from its macro- form has 
been well described [13]. This utilizes the principle that PEG acts as a solvent sponge, 
causing the concentration of proteins in the water space to rise until their solubility is 
exceeded and they precipitate. Generally, larger proteins have lower solubility than smaller 
proteins, and macro-PRL is precipitated at a PEG concentration of 25% while the monomeric 
form remains in solution. 
The general principles of PEG precipitation of macro-complexes can be applied to any 
smallish molecule bound to an immunoglobulin. There have been reports of macro-TSH 
being investigated with PEG precipitation [16, 54] and also troponin [30, 55]. However, the 
behaviour of any assay used in conjunction with PEG precipitation needs to be carefully 
validated before use. 
 
6 Serial dilutions 
Serial dilutions (1:2, 1:4, 1:8 etc) are a possible means of looking for interferences. The 
simple concept is that in the absence of an interferent, as a sample is progressively diluted, 
the measured concentration of that analyte should progressively fall in linear/parallel 
fashion. In the presence of an interferent, it would be anticipated that there would be non-
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linearity and non-parallelism. However, with immunoassay there are many potential 
confounders such as assay configuration, relative affinity of the assay and interfering 
antibodies, antibody valency and steric hindrance to identify a few [56]. 
 
Consideration must be given as to whether dilution studies should be performed with a zero 
diluent or a patient sample containing zero concentration of the analyte in question as the 
matrix may be more or less important in different assays with items such as 
immunoglobulins in patient material having an effect. 
  
Significant deviation from linearity can be taken as supporting the presence of an interfering 
substance but apparent parallelism does not prove the absence of an interferent. 
 
7 Check using another matrix 
Some analytes such as hCG (and metabolites) are small enough to be readily filtered by the 
renal glomerulus and appear in substantial quantities in the urine in conditions such as early 
pregnancy. Indeed this formed the basis for pregnancy testing [57].  
Immunoglobulins are large molecules and not filtered by the glomerulus, so if serum hCG 
appears to be inappropriately detected, then hCG analysis of a urine sample collected at the 
same time may determine whether the raised hCG is real or the result of an interference. 
Similarly, an apparently inappropriately low serum hCG can be checked with a urine sample 
and a high urine hCG would support the presence of a negative interference [58]. 
 
8 Dosing for suspected negative interference 
Negative interference has been detected by dilution of the sample using assay diluent [59, 
60]. An alternate suggested approach is as follows. If a result is suspected of being falsely 
low, i.e. a negative interference is suspected, then doing serial dilutions upwards can be 
performed using a patient sample with a high concentration of the analyte under 
investigation. At a 1:1 dilution an intermediate concentration should be obtained. Linearity 
and parallelism can be assessed with serial dilutions but the same provisos as for Serial 
Dilutions above hold. 
 
All of the above techniques can be utilised in small non-specialist laboratories. A combination of 
these different procedures will usually identify that a positive interference is present. Where 
uncertainty exists, especially if a false negative interference is suspected, then referral to, or 
discussion with a specialist laboratory is indicated. 
 
Specialised investigations 
Extraction may be performed with organic solvents to denature possible interfering proteins and 
separate charged molecules (eg steroid glucuronides) from relatively uncharged molecules such as 
cortisol. 
 Potentially interfering immunoglobulins may be extracted by incubation with an immunoglobulin-
binding molecule such as protein A or protein G [61].  
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Gel filtration column chromatography using an agent such as Sephacryl 300 which has a separation 
range of approximately 10,000 – 1,500,000 daltons MW enables the molecular weight associated 
with the analyte to be defined [30]. 
Measurement of steroid hormones by LC-MS/MS is now performed routinely in reference 
laboratories. These procedures include sample extraction to remove proteins, and the ability of the 
technique to separate and identify structurally similar molecules overcomes the specificity problems 
of direct immunoassay [62].  
 
Conclusions  
Immunoassay is no place for optimists. Interferences can and do occur and they will not be identified 
unless analysts are alert and suspicious regarding the results they put out. 
While tools such as heterophile blocking tubes are widely believed to be all the investigation that is 
needed for possible interferences, as indicated in the text above, it appears that they do not work 
reliably in assays using murine antibodies and these are the commonest antibodies used in 
immunoassay laboratories. 
It is quite feasible to have a small armamentarium of secondary investigations available to 
investigate possible interferences as outlined above, and all immunoassay laboratories should have 
some or all of these set up. 
When all else fails, ensure you have a contact in a sophisticated laboratory where a variety of more 
sophisticated procedures are available. 
As a final note of caution, remember that positive interferences are frequently more obvious than 
negative interferences. 
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Table 1:  Interferences in immunoassay 
Analyte-dependent interferences 
x Cross reacting substances (lack of specificity)  
o Pharmacy 
 eg prednisolone cross-reacting in cortisol assays 
o Metabolic 
 Metyrapone therapy and 11-deoxycortisol cross-reacting in cortisol assays 
o Disease states 
 CKD – conjugates of 5alpha-tetrahydrocortisol cross reacting in serum 
cortisol assays in persons with renal disease 
 CKD  C-terminal fragments interfering in2-site immunometric PTH assays 
x Endogenous antibodies  
o Reagent antibodies (heterophile; HAAA) 
o  Analyte autoantibody (macro complexes) 
x Hook effect in 2-site immunometric and nephelometric assays for tumour marker markers 
x Binding proteins 
o OCP and TBG or CBG 
x Idiopathic 
x Pre-analytical 
o Renin cryoactivation 
 
Analyte-independent interferences 
x Pre-analytical 
o Inadequate centrifugation with microclots 
o Haemolysis, lipemia, icterus 
o Carryover from very high concentration analyte eg hCG or tumour markers 
x Analytical 
o Inadequate separation from binding proteins 
o Antibodies directed against labels eg ruthenium 
o Interference with signal generation by therapeutic ingestion of similar agent eg 
biotin 
o Disease states may cause artifactual changes in analytes eg FFA displacing T4 from 
binding proteins 
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Table 2: Changing specificity of cortisol assays 
Specificity of  Cortisol Assays (serum steroids) 2014  
 Cross Reactivity (%)  
 Roche Centaur  Immulite  DXi  Architect 
Cortisol  100  100  100  100  100  
Corticosterone  5.8  5.3  1.2  2.1  0.9  
Cortisone  0.3  31.1  1.0  8.1  2.7  
l l-deoxycortisol  4.1  23.3  1.6  17.8  1.9  
17-α-OH-progesterone  1.5  1.2  0.2  5.3  0.6  
Progesterone  0.4  <0.1  <0.1  0.50  <0.1  
l l-deoxycorticosterone  0.7  1.8  <0.1  0.9  <0.1  
Prednisolone  171  109  62  7.6  12.3  
5α-tetrahydrocortisol  165  6.5   ??  ??  
Fludrocortisone  Not tested  Not tested  ??  Not 
tested  
36.6  
Dexamethasone  <0.1  0.2  <0.1  <0.1  <0.1  
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Specificity of  Cortisol Assays (serum steroids) 2017  
 Cross Reactivity (%)  
 Roche Centaur  Immulite  DXi  Architect 
Cortisol  100  100  100  100  100  
Corticosterone  2.5  5.3  1.2  2.1  0.9  
Cortisone  6.6  31.1  1.0  8.1  2.7  
l l-deoxycortisol  4.9  23.3  1.6  17.8  1.9  
17-α-OH-progesterone  <0.1  1.2  0.2  5.3  0.6  
Progesterone  0.4  <0.1  <0.1  0.50  <0.1  
l l-deoxycorticosterone  0.6  1.8  <0.1  0.9  <0.1  
Prednisolone  8  109  62  23.9  12.3  
5α-tetrahydrocortisol     <0.1  0.5?  
Fludrocortisone  0.2     36.6  
Dexamethasone  <0.1  0.2  <0.1  <0.1  <0.1  
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